COMBINATION OF CHEMOTHERAPY AND HORMONE-THERAPY IN ADVANCED BREAST-CANCER

被引:0
作者
MERKLE, E [1 ]
BAR, I [1 ]
HENKE, A [1 ]
BUHNER, M [1 ]
WILDT, L [1 ]
MARTUS, P [1 ]
LANG, N [1 ]
机构
[1] UNIV ERLANGEN NURNBERG,INST MED STAT & DOKUMENTAT,W-8520 ERLANGEN,GERMANY
关键词
ADVANCED BREAST CANCER; COMBINED THERAPY; DECAPEPTYL(R); RESPONSE RATE;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In a prospective study at the Department of Obstetrics and Gynaecology, University of Erlangen, patients with advanced breast carcinoma were treated with a combination of chemotherapy and hormone therapy. Patients received one injection of Decapeptyl(R) in a 28 days interval. At day 12 and 13 of the treatment cycle 40 mug of ethinylestradiol were applicated followed by intravenous chemotherapy with 500 mg/m2 fluorouracil, 10 mg/m2 mitoxantrone and 500 mg/m2 cyclophosphamide took place on day 14. 39 patients were integrated in this study. All of these patients were evaluable regarding the side-effects and 36 patients concerning the response rate. In case of response after 6 cycles the interval between the chemotherapy was prolonged to 6 weeks and the Decapeptyl(R) injections remained in a 4 weeks interval. 15 patients received this combined therapy as a first-line therapy, 24 patients as a second-line therapy or third-line therapy. 2 patients had a complete remission, 14 patients had a partial remission. The objective response rate (CR+PR) was therefore 44 %. In 8 patients the response was classified as no change, consequently the total response rate (CR + PR + NC) was 67 %. 12 patients showed a progression (33 %), 2 patients with several previous treatments suffered an early progress. 3 patients did not finish the therapy. The median response duration was 9 months and the median follow up time until now is 13 months; 24 patients died. Therapy related side-effects were tolerable. As the most frequent side-effect bone marrow suppression were observed. Subjective, for the patients most inconvenient side-effects like nausea, vometing, and alopecia seldomly appeared. The combination of chemotherapy and hormone therapy achieved with a good toleration response rates, which are compatible to international standards of chemotherapy. The exspectations to achieve a better remission rate by a combination of chemotherapy and hormone therapy rather than chemotherapy alone were not fulfilled in this studie.
引用
收藏
页码:220 / 223
页数:4
相关论文
共 50 条
  • [31] Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer
    P Poikonen
    J Sjöström
    R-M Amini
    K Villman
    J Ahlgren
    C Blomqvist
    British Journal of Cancer, 2005, 93 : 515 - 519
  • [32] Epidemiology and economics of chemotherapy combinations in the treatment of advanced breast cancer
    Martin, JP
    Diéras, V
    Berdeaux, G
    THERAPIE, 2000, 55 (01): : 127 - 131
  • [33] Chemotherapy for Advanced Breast Cancer – How Long Should it Continue?
    Martin R Stockler
    Nicholas JC Wilcken
    Alan S Coates
    Breast Cancer Research and Treatment, 2003, 81 (Suppl 1) : 49 - 52
  • [34] Do patients with advanced breast cancer benefit from chemotherapy?
    Ramirez, AJ
    Towlson, KE
    Leaning, MS
    Richards, MA
    Rubens, RD
    BRITISH JOURNAL OF CANCER, 1998, 78 (11) : 1488 - 1494
  • [35] Immune gene expression and response to chemotherapy in advanced breast cancer
    Theodoros Foukakis
    John Lövrot
    Alexios Matikas
    Ioannis Zerdes
    Julie Lorent
    Nick Tobin
    Chikako Suzuki
    Suzanne Egyházi Brage
    Lena Carlsson
    Zakaria Einbeigi
    Barbro Linderholm
    Niklas Loman
    Martin Malmberg
    Mårten Fernö
    Lambert Skoog
    Jonas Bergh
    Thomas Hatschek
    British Journal of Cancer, 2018, 118 : 480 - 488
  • [36] Immune gene expression and response to chemotherapy in advanced breast cancer
    Foukakis, Theodoros
    Lovrot, John
    Matikas, Alexios
    Zerdes, Ioannis
    Lorent, Julie
    Tobin, Nick
    Suzuki, Chikako
    Brage, Suzanne Egyhazi
    Carlsson, Lena
    Einbeigi, Zakaria
    Linderholm, Barbro
    Loman, Niklas
    Malmberg, Martin
    Ferno, Marten
    Skoog, Lambert
    Bergh, Jonas
    Hatschek, Thomas
    BRITISH JOURNAL OF CANCER, 2018, 118 (04) : 480 - 488
  • [37] Second-Line Combination Chemotherapy with Vinorelbine and Capecitabine in Patients with Advanced Breast Cancer Previously Treated with Anthracyclines and/or Taxanes
    Mao, Weidong
    Guan, Xunxing
    Tucker, Steven
    Li, Fengyan
    He, Zhenyu
    Wang, Junjie
    Guo, Jun
    Wu, Shangang
    CHEMOTHERAPY, 2011, 57 (01) : 71 - 76
  • [38] A MULTIVARIATE-ANALYSIS OF PROGNOSTIC FACTORS INCLUDING TUMOR RESPONSE AFTER ENDOCRINE THERAPY IN ADVANCED BREAST-CANCER PATIENTS
    NOMURA, Y
    TASHIRO, H
    OSAKI, A
    ONCOLOGY, 1995, 52 (05) : 376 - 380
  • [39] Endocrine therapy for hormone treatment-naive advanced breast cancerf
    Martin, Miguel
    Lopez-Tarruella, Sara
    Jerez Gilarranz, Yolanda
    BREAST, 2016, 28 : 161 - 166
  • [40] WEEKLY 5-FLUOROURACIL AND HIGH-DOSE FOLINIC ACID IN COMBINATION WITH EPIDOXORUBICIN AS FIRST-LINE THERAPY IN ADVANCED BREAST-CANCER - A PHASE-II STUDY
    STOGER, H
    BAUERNHOFER, T
    KASPAREK, AK
    SCHMID, M
    MOSER, R
    PLONER, F
    DERSTVENSCHEG, E
    KUSS, I
    WILDERSTRUSCHNIG, M
    STEINDORFER, P
    ROSANELLI, G
    SAMONIGG, H
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1994, 34 (01) : 75 - 78